Beam Therapeutics (BEAM)
US Market

Beam Therapeutics (BEAM) Financial Statements


Beam Therapeutics Financial Overview

Beam Therapeutics's market cap is currently ―. The company's EPS TTM is $-1.781; its P/E ratio is -14.56; Beam Therapeutics is scheduled to report earnings on August 6, 2024, and the estimated EPS forecast is $-1.14. See an overview of income statement, balance sheet, and cash flow financials.
Mar 24Dec 23Sep 23Jun 23Mar 23
Income Statement-
Total Revenue$ 7.41M$ 316.19M$ 17.19M$ 20.12M$ 24.21M
Gross Profit$ 7.41M$ 316.19M$ 17.19M$ 20.12M$ 24.21M
EBIT$ -110.39M$ 144.16M$ -96.09M$ -82.78M$ -96.46M
EBITDA$ -104.95M$ 149.53M$ -90.90M$ -77.96M$ -91.81M
Net Income Common Stockholders$ -98.67M$ 142.80M$ -96.09M$ -82.78M$ -96.46M
Balance Sheet-
Cash, Cash Equivalents and Short-Term Investments$ 1.09B$ 435.89M$ 1.02B$ 1.07B$ 1.06B
Total Assets$ 1.36B$ 1.46B$ 1.29B$ 1.35B$ 1.33B
Total Debt$ 168.12M$ 172.69M$ 173.98M$ 177.13M$ 178.86M
Net Debt$ -926.43M$ -263.21M$ -841.48M$ -895.89M$ -880.61M
Total Liabilities$ 446.31M$ 478.38M$ 511.59M$ 542.24M$ 570.85M
Stockholders Equity$ 913.49M$ 981.33M$ 778.94M$ 811.64M$ 761.51M
Cash Flow-
Free Cash Flow$ -102.19M$ 131.48M$ -97.73M$ -100.85M$ -115.83M
Operating Cash Flow$ -99.75M$ 135.07M$ -89.78M$ -84.67M$ -109.81M
Investing Cash Flow$ -53.46M$ 98.10M$ -10.23M$ -41.48M$ 25.45M
Financing Cash Flow$ 2.90M$ 33.71M$ 36.78M$ 107.54M$ 98.42M
Currency in USD

Beam Therapeutics Earnings and Revenue History

Beam Therapeutics Debt to Assets

Beam Therapeutics Cash Flow

Beam Therapeutics Forecast EPS vs Actual EPS

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis